• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Western Pac Surveill Response J . Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and th

tetano

Editor, Senior Moderator
Western Pac Surveill Response J


. 2025 Jun 4;16(2):1-8.
doi: 10.5365/wpsar.2025.16.2.1157. eCollection 2025 Apr-Jun. Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics

Takeshi Arashiro[SUP] 1 2 3 4 5 [/SUP], Regina Pascua Berba[SUP] 6 [/SUP], Joy Potenciano Calayo[SUP] 7 [/SUP], Rontgene Solante[SUP] 8 [/SUP], Shuichi Suzuki[SUP] 9 [/SUP], Jinho Shin[SUP] 5 [/SUP], Motoi Suzuki[SUP] 3 [/SUP], Martin Hibberd[SUP] 1 [/SUP], Koya Ariyoshi[SUP] 2 [/SUP], Chris Smith[SUP] 1 2 [/SUP]



Affiliations
Abstract

Problem: Once COVID-19 vaccines were rolled out, there was a need to monitor real-world vaccine effectiveness to accumulate evidence to inform policy and risk communication. This was especially true in Japan and the Philippines, given historical issues that affected vaccine confidence.
Context: Neither country had public health surveillance that could be enhanced to evaluate vaccine effectiveness or readily available national vaccination databases.
Action: Study groups were established in multiple health-care facilities in each country to assess vaccine effectiveness against both symptomatic infection and severe disease.
Outcome: In Japan, multiple study reports were published in Japanese on the web site of the National Institute of Infectious Diseases and presented at the national government's advisory board. Nationwide media coverage facilitated transparency and increased the confidence of the government and the public in the vaccination programme. In the Philippines, the launch of the study was delayed so as to align the research plan with the interests of various stakeholders and to obtain institutional review board approval. Ultimately, the studies were successfully initiated and completed.
Discussion: There were four main challenges in conducting our studies: finding health-care facilities for data collection; obtaining exposure (vaccination) data; identifying epidemiological biases and confounders; and informing policy and risk communication in a timely manner. Preparedness during inter-emergency/epidemic/pandemic periods to rapidly evaluate relevant interventions such as vaccination is critical and should include the following considerations: (1) the establishment and maintenance of prospective data collection platforms, ideally under public health surveillance (if not, clinical research networks or linked databases); (2) uniform and practical protocols considering biases and confounders; and (3) communication with stakeholders including institutional review boards.


 
Back
Top Bottom